Pharming Group to Present Eight Abstracts on Leniolisib at CIS Congress
Pharming Group announced on Thursday a series of presentations at the annual congress of the Clinical Immunology Society (CIS), taking place from May 6 to May 9 in New Orleans. These presentations will focus on the study results of leniolisib in patients with rare immunological disorders, particularly APDS syndrome.
Eight Presentations Focused on Leniolisib and Primary Immunodeficiencies
Pharming and its collaborators will present eight communications covering several clinical areas. Among these are the interim results of a long-term extension study of leniolisib in pediatric patients aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS).
Other presentations will focus on the clinical experience of leniolisib in expanded access for treating immune dysregulation in patients with common variable immune deficiencies (CVID) and CVID-like disorders. The program also includes a presentation on the demographic and clinical characteristics of pediatric APDS syndrome, as well as data on symptoms reported by patients and caregivers.
Two Ongoing Phase II Trials for CVID and Other Immunodeficiencies
Two phase II clinical trials (NCT06897358 and NCT06549114) are currently underway to assess the safety and tolerability of leniolisib in patients with CVID and primary immunodeficiencies with immune dysregulation beyond APDS syndrome.
Anurag Relan, Medical Director at Pharming, commented, 'We are pleased to present data at CIS that advances the understanding of APDS syndrome and other primary immunodeficiencies characterized by immune dysregulation. Observations from clinical experience support ongoing clinical trials evaluating leniolisib in CVID and CVID-like disorders, and we look forward to the results in the second half of this year.'
